1. Home
  2. RMCO vs FEMY Comparison

RMCO vs FEMY Comparison

Compare RMCO & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royalty Management Holding Corporation

RMCO

Royalty Management Holding Corporation

SELL

Current Price

$2.38

Market Cap

45.7M

Sector

Miscellaneous

ML Signal

SELL

Logo Femasys Inc.

FEMY

Femasys Inc.

HOLD

Current Price

$0.86

Market Cap

51.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RMCO
FEMY
Founded
2021
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Medical/Dental Instruments
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
45.7M
51.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RMCO
FEMY
Price
$2.38
$0.86
Analyst Decision
Buy
Strong Buy
Analyst Count
1
3
Target Price
N/A
$6.83
AVG Volume (30 Days)
71.5K
1.9M
Earning Date
11-13-2025
11-14-2025
Dividend Yield
0.41%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,798,352.00
$2,061,502.00
Revenue This Year
$531.90
$64.02
Revenue Next Year
$200.00
$147.19
P/E Ratio
N/A
N/A
Revenue Growth
445.90
63.53
52 Week Low
$0.91
$0.31
52 Week High
$4.76
$1.80

Technical Indicators

Market Signals
Indicator
RMCO
FEMY
Relative Strength Index (RSI) 45.66 53.08
Support Level $2.32 $0.79
Resistance Level $2.61 $0.91
Average True Range (ATR) 0.28 0.07
MACD 0.02 -0.01
Stochastic Oscillator 49.04 34.37

Price Performance

Historical Comparison
RMCO
FEMY

About RMCO Royalty Management Holding Corporation

Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.

About FEMY Femasys Inc.

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Share on Social Networks: